TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2014

A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Barbara J Gitlitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.